Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
39M
-
Shares change
-
+1.27M
-
Total reported value, excl. options
-
$292M
-
Value change
-
-$5.07M
-
Put/Call ratio
-
1.49
-
Number of buys
-
63
-
Number of sells
-
-59
-
Price
-
$7.47
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2019
179 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2019.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39M shares
of 108M outstanding shares and own 36.2% of the company stock.
Largest 10 shareholders include FMR LLC (6.13M shares), VANGUARD GROUP INC (4.18M shares), WASATCH ADVISORS INC (4.02M shares), BlackRock Inc. (3.98M shares), Bellevue Group AG (2.59M shares), DIMENSIONAL FUND ADVISORS LP (1.76M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1.43M shares), MILLENNIUM MANAGEMENT LLC (1.24M shares), SAMLYN CAPITAL, LLC (1.18M shares), and STATE STREET CORP (1.16M shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.